Investigational drug · Phase 2
SR1375
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Community-acquired Pneumonia.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 9, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "SR1375"
First trial start
2024
Sep 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SR1375", any sponsor or status.
Conditions studied
As listed on its trial records.
- Community-acquired Pneumonia
Approved drugs for the same conditions: Pneumonia
Largest trials
Live from ClinicalTrials.gov: studies naming "SR1375" as an intervention, largest first.
- Efficacy and Safety of SR1375 in Adult Patients With CAPPivotal-lookingRecruiting
Shanghai SIMR Biotechnology Co., Ltd.Industry
NCT06577558 · 240 participants (planned) · Start Sep 10, 2024 · Primary completion Oct 15, 2025
Drug: SR1375 capsule 3mg+regular treatments; SR1375 capsule 1mg+regular treatments and 2 more · For: Community-acquired Pneumonia
Sites: Fuyang, China; Beijing, China; Zhangzhou, China · 29 sites in all
Shanghai SIMR Biotechnology Co., Ltd.Industry
NCT05026008 · 72 participants · Start Sep 30, 2021 · Primary completion Nov 30, 2022
Drug: SR1375; Matching placebo · For: Healthy Volunteers
Sites: Nedlands, Australia
Shanghai SIMR Biotechnology Co., Ltd.Industry
NCT05421923 · 32 participants · Start Jun 24, 2022 · Primary completion Oct 5, 2022
Drug: SR1375 capsules · For: Healthy
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Community-acquired Pneumonia
- RaphaminMMH-407Phase 35 trials
Materia Medica Holding · Rhinosinusitis, Rhinosinusitis Acute, Cystitis Chronic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.